P O Szapary

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol
    P O Szapary
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Curr Opin Pharmacol 1:113-20. 2001
  2. ncbi Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial
    Philippe O Szapary
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    JAMA 290:765-72. 2003
  3. ncbi Physical activity and its effects on lipids
    Philippe O Szapary
    Division of General Internal Medicine, University of Pennsylvania School of Medicine, 1222 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Curr Cardiol Rep 5:488-92. 2003
  4. ncbi The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Philippe O Szapary
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA
    Am Heart J 148:211-21. 2004
  5. ncbi A randomized trial of a low-carbohydrate diet for obesity
    Gary D Foster
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    N Engl J Med 348:2082-90. 2003
  6. ncbi Antidiabetic action of bezafibrate in a large observational database
    James H Flory
    1Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Diabetes Care 32:547-51. 2009
  7. ncbi Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial
    LeAnne T Bloedon
    Division of General Internal Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    J Am Coll Nutr 27:65-74. 2008
  8. ncbi The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans
    Bonnie Ky
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    J Am Coll Cardiol 51:1653-62. 2008
  9. ncbi Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
    Philippe O Szapary
    Division of General Internal Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:182-8. 2006
  10. ncbi Flaxseed and cardiovascular risk
    LeAnne T Bloedon
    School of Nursing, The Center for Experimental Therapeutics, Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6021, USA
    Nutr Rev 62:18-27. 2004

Research Grants

  1. Flax: Safety & Efficacy in Reducing Cardiovascular Risk
    Philippe Szapary; Fiscal Year: 2003
  2. AYURVEDIC HERBALS: EFFECTS ON LIPIDS & ATHEROSCLEROSIS
    Philippe Szapary; Fiscal Year: 2004
  3. Chromium Picolinate in the Metabolic Syndrome
    Nayyar Iqbal; Fiscal Year: 2004

Detail Information

Publications13

  1. ncbi Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol
    P O Szapary
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Curr Opin Pharmacol 1:113-20. 2001
    ..More research is needed to further define the role of fibrates when used alone and in combination with statins in high-risk individuals...
  2. ncbi Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial
    Philippe O Szapary
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    JAMA 290:765-72. 2003
    ..However, there are currently no published safety or efficacy data on the use of guggul extracts in Western populations...
  3. ncbi Physical activity and its effects on lipids
    Philippe O Szapary
    Division of General Internal Medicine, University of Pennsylvania School of Medicine, 1222 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Curr Cardiol Rep 5:488-92. 2003
    ....
  4. ncbi The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Philippe O Szapary
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA
    Am Heart J 148:211-21. 2004
    ..More clinical trial data is needed to test the hypothesis that pharmacologic therapy targeting the TG-HDL axis reduces atherosclerosis and cardiovascular events...
  5. ncbi A randomized trial of a low-carbohydrate diet for obesity
    Gary D Foster
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    N Engl J Med 348:2082-90. 2003
    ..Despite the popularity of the low-carbohydrate, high-protein, high-fat (Atkins) diet, no randomized, controlled trials have evaluated its efficacy...
  6. ncbi Antidiabetic action of bezafibrate in a large observational database
    James H Flory
    1Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Diabetes Care 32:547-51. 2009
    ..The purpose of this study was to test the hypothesis that bezafibrate, an approved fibrate, can prevent or delay type 2 diabetes...
  7. ncbi Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial
    LeAnne T Bloedon
    Division of General Internal Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    J Am Coll Nutr 27:65-74. 2008
    ..We studied the effects of flaxseed on markers of cardiovascular risk in hypercholesterolemic adults...
  8. ncbi The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans
    Bonnie Ky
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    J Am Coll Cardiol 51:1653-62. 2008
    ..The aim of this study was to determine the effects of pravastatin and atorvastatin on markers of oxidative stress in plasma...
  9. ncbi Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
    Philippe O Szapary
    Division of General Internal Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:182-8. 2006
    ..These results suggest that PIO has direct effects on HDL, which may contribute to its antiatherogenic effects...
  10. ncbi Flaxseed and cardiovascular risk
    LeAnne T Bloedon
    School of Nursing, The Center for Experimental Therapeutics, Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6021, USA
    Nutr Rev 62:18-27. 2004
    ..Data on the antiplatelet, antioxidant, and hypotensive effects of flaxseed, however, are inconclusive. More research is needed to define the role of this functional food in reducing cardiovascular risk...
  11. ncbi Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults
    Nayyar Iqbal
    Division of General Internal Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
    Metab Syndr Relat Disord 7:143-50. 2009
    ..The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome...
  12. ncbi Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse models
    Michael A Pellizzon
    M D, Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, 421 Curie Blvd, BRB II III, Philadelphia, PA 19104 6160, USA
    J Am Coll Nutr 26:66-75. 2007
    ....
  13. ncbi Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome
    Frederick F Samaha
    Cardiovascular Division, Department of Medicine, Cardiovascular Institute, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Arterioscler Thromb Vasc Biol 26:624-30. 2006
    ..However, the full spectrum of potentially antiatherogenic mechanisms of PPAR-gamma agonists have not been fully tested in nondiabetic patients with metabolic syndrome...

Research Grants3

  1. Flax: Safety & Efficacy in Reducing Cardiovascular Risk
    Philippe Szapary; Fiscal Year: 2003
    ..abstract_text> ..
  2. AYURVEDIC HERBALS: EFFECTS ON LIPIDS & ATHEROSCLEROSIS
    Philippe Szapary; Fiscal Year: 2004
    ..These studies will help define the role of these herbal therapies in the prevention of atherosclerosis, and serve as a model for the critical evaluation of dietary supplements in cardiovascular disease. ..
  3. Chromium Picolinate in the Metabolic Syndrome
    Nayyar Iqbal; Fiscal Year: 2004
    ..The results from this clinical trial will provide ample preliminary data for future R01 grant submissions further investigating the effects of CrPic supplementation in diabetes and coronary heart disease prevention. ..